Efficacy and safety of PD-1 inhibitor combined with anlotinib in the treatment of advanced neuroendocrine cancer: A single-center retrospective study
#3160
Introduction: Neuroendocrine carcinoma is a group of poorly differentiated and highly malignant tumors. There is no standard follow-up treatment regimen after the failure of first-line treatment.
Aim(s): We aimed to analyse the efficacy and safety of PD-1 inhibitor combined with anlotinib in the treatment of advanced neuroendocrine carcinoma in lung and digestive tract.
Materials and methods: From January 2018 to June 2020, the data of patients with advanced neuroendocrine carcinoma who had failed first-line standard chemotherapy and were treated with programmed death receptor-1 (PD-1) inhibitor combined with anlotinib were collected.
Conference: 18th Annual ENETS Concerence (2021)
Presenting Author:
Keywords: immune checkpoint inhibitor, anlotinib, neuroendocrine carcinoma,
To read the full abstract, please log into your ENETS Member account.